AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that an abstract on NeuroRestore ACD856 and its positive effects on brain activity in the MAD clinical trial has been accepted for presentation at the annual Alzheimer's conference CTAD, Clinical Trials in Alzheimer's Disease, which this year is being held in San Francisco, November 29 – December 2.
The abstract, titled Quantitative EEG results from a multiple ascending dose study in healthy volunteers with NeuroRestore ACD856, a positive modulator of Neurotrophin Trk-receptors, will be presented at the international Alzheimer conference CTAD 2022 by Dr. Johan Sandin, CSO at AlzeCure. The other co-authors are Kristin Önnestam, project leader, Boel Nilsson, Dr. Matthias Rother, Dr. Erik Rein-Hedin, Dr. Peter Anderer, Manuel Kemethofer, Dr. Magnus Halldin, Director of Discovery DMPK & Safety assessment, Dr. Gunnar Nordvall, Director of Medicinal Chemistry at AlzeCure, Dr. Pontus Forsell, Head of Discovery & Research at AlzeCure, and Dr. Märta Segerdahl, Head of Development and CMO at AlzeCure.
The presentation contains results from the clinical phase I MAD study with ACD856, the leading drug candidate within the NeuroRestore platform, which exhibits both good tolerability and good pharmacokinetic properties in humans. The substance was also shown to pass over the blood-brain barrier in high and relevant concentrations where it activates relevant neuronal pathways in the brain, something that is reflected in EEG measurements in the test subjects.
"These new positive clinical results show central target engagement of ACD856, i.e. that the substance reaches and activates the target organ – the brain. The brain activation observed supports the continued clinical development of the substance in both cognitive disorders and depression," said Johan Sandin, CSO at AlzeCure Pharma.
"We are very happy that we will have the opportunity to present our data at such a prestigious Alzheimer's conference as CTAD. NeuroRestore ACD856 has shown very good clinical results and these EEG-data will further strengthen the external interest in the project," said Martin Jönsson, CEO of AlzeCure Pharma.
The abstract and poster will be available on AlzeCure's website after the presentation (https://www.alzecurepharma.se/en/presentations-and-interviews/).
